Search Results
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
Baxter to Host Annual Meeting of Stockholders in Virtual Format
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting. Online access to the 2024 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2024 Annual Meeting in person.
'Passionate & Precise' about Kidney Care
Renal Therapy Services (RTS) training specialist shares his journey with kidney disease and the opportunity he has every day to make an impact on other patients’ lives.
Finding Hope: Empowering Patients’ Kidney Care Journeys
About 850 million people are living with kidney disease globally; we estimate nearly 10 million of them have reached end-stage kidney disease and require access to dialysis or transplant.1
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024. About Baxter
Baxter Reinforces Guidance Regarding Urgent Medical Device Correction for Exactamix Pro Due to Software Overfill Error
Baxter International Inc. is reinforcing guidance regarding an Urgent Medical Device Correction for ExactaMix Pro 1200 and ExactaMix Pro 2400 compounders using software versions 2.0.8 and 2.1.8. Baxter notified impacted customers initially in December 2023 and again in February 2024. The Correction is due to an error in the "Use Some Overfill" feature, which may lead to over-delivery of an ingredient into the final admixture.
‘My Colleagues Saved my Son’s Life’
When Rachel Longman joined Baxter, she had no way of knowing that the company would play a huge part in providing life-saving treatment for her son, Milo, when he was diagnosed with an unexpected illness.
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.